News

Systematic review of over 300 randomized clinical trials sought to determine how often these values were overestimated in contemporary cardiovascular trials.

Johnson & Johnson’s novel targeted therapy TAR-200 produced a greater than 80% complete response rate in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer with carcinoma in situ.

In the fourth and final part of this video interview with ACT editor Andy Studna, Rohit Nambisan, CEO & founder of Lokavant looks into the future of feasibility studies, the integration of AI, and how they are driving more personalized approaches.

How innovative trial designs and advanced imaging modalities can address the challenges of early drug development to optimize outcomes for patients with solid tumors.

In part 3 of this video interview with ACT editor Andy Studna, Rohit Nambisan, CEO & founder of Lokavant analyzes some of the most common mistakes he has seen stakeholders make in feasibility studies and how they can be addressed.

Partnership expected to utilize Walgreens’ pharmacies as recruitment and trial sites for a clinical study regarding obesity, weight issues, and type 2 diabetes, mainly in historically underrepresented groups.

The combination of Calquence (acalabrutinib; AstraZeneca) plus bendamustine and rituximab generated a clinically meaningful improvement in progression-free survival in the first-line treatment of adults with mantle cell lymphoma.

In part 2 of this video interview with ACT editor Andy Studna, Rohit Nambisan, CEO & founder of Lokavant touches on structuring feasibility studies and how they can make running a trial more efficient.

Survey study assessed 58 cancer centers in the United States to identify their greatest challenges.

In part 1 of this video interview with ACT editor Andy Studna, Rohit Nambisan, CEO & founder of Lokavant discusses use cases for artificial intelligence in clinical trials and how it can enhance patient centricity.

As adoption increases, regulatory bodies are becoming more involved in the oversight of artificial intelligence.

Data from the Phase III STRIDE-10 trial showed V116 produced immune responses against the serotypes responsible for the majority of adult invasive pneumococcal disease.

New amendment explicitly states that in vitro diagnostic products are devices under the Federal Food, Drug, and Cosmetic Act.

Despite the significance offered by AI to pharmaceutical companies, there are several challenges that must be overcome for successful integration of tech-based tools.

Under new multi-year strategic partnership, Parexel will utilize Palantir’s artificial intelligence platform.

Enhertu, a HER2-directed antibody-drug conjugate, showed a clinically meaningful survival benefit in progression-free survival among patients with HR-positive, HER2-low metastatic breast cancer.

Phase II/III COMPANION-002 trial shows promise of CTX-009 in combination with paclitaxel for patients with metastatic or locally advanced biliary tract cancer.

In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.

Analysis of randomized clinical trial for migraine sought to determine whether there were differences between outcomes from patients assigned to roles and those as healthy controls.

Rinvoq (upadacitinib) shows efficacy in both itch resolution and skin clearance in the treatment of patients with atopic dermatitis.

In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.

Cross-sectional comparative study of over 36,000 patients with diabetes found differences in the two groups, suggesting a need for broader patient criteria in trials.

Felix addresses a variety of topics around artificial intelligence including challenges, streamlining data management, and human intervention.

Data from part one of the Phase III RUBY trial show Jemperli (dostarlimab) plus chemotherapy produced a statistically significant and clinically meaningful survival benefit in patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient/microsatellite stable tumors.

A representative sample patient population that accurately reflects the overall population is vital to establish the safety and efficacy of a drug.

Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.

In part 2 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses best practices for understanding specific therapeutic areas and deploying an effective eCOA strategy.

In part 1 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA touches on how the use of clinical outcome assessments differs across therapeutic areas.